Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) shot up 6.3% during mid-day trading on Thursday . The stock traded as high as $33.50 and last traded at $33.50. 43,640 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 137,913 shares. The stock had previously closed at $31.50.
Analyst Ratings Changes
Several equities research analysts have commented on the company. William Blair upgraded LENZ Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. HC Wainwright reissued a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Finally, Raymond James began coverage on shares of LENZ Therapeutics in a report on Friday, September 27th. They set an "outperform" rating and a $37.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $35.40.
View Our Latest Stock Analysis on LENZ
LENZ Therapeutics Stock Performance
The company's 50-day moving average is $32.18 and its 200-day moving average is $25.44.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter in the previous year, the firm posted ($1.33) earnings per share. Analysts predict that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in LENZ Therapeutics during the 3rd quarter worth $107,000. Squarepoint Ops LLC acquired a new position in LENZ Therapeutics during the second quarter worth $181,000. MetLife Investment Management LLC purchased a new position in shares of LENZ Therapeutics in the 3rd quarter valued at about $182,000. GSA Capital Partners LLP acquired a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at approximately $246,000. Finally, Jane Street Group LLC purchased a new stake in LENZ Therapeutics during the third quarter worth $286,000. 54.32% of the stock is owned by institutional investors and hedge funds.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
